Mental state: significant response or improvement in negative symptoms (PANSS negative subscale, high = worse) ‐ short term (12 weeks) · adults with schizophrenia
It is very uncertain whether noradrenaline reuptake inhibitors changes mental state: significant response or improvement in negative… compared with placebo (very low certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · adults with schizophrenia
1 finding from 1 review
Clinical global response: significant response or improvement in global status (CGI‐S, high = worse) ‐ short term (4 weeks) · adults with schizophrenia
It is very uncertain whether noradrenaline reuptake inhibitors changes clinical global response: significant response or improvement in… compared with placebo (very low certainty).
1 finding from 1 review
Cognitive functioning: significant response or improvement in cognitive functioning · adults with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive function: average endpoint score** · adults with schizophrenia
1 finding from 1 review
QoL · adults with schizophrenia
1 finding from 1 review
Nausea · adults with schizophrenia
Noradrenaline reuptake inhibitors showed no clear difference in adverse effects: Nausea ‐ short term (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Leaving the study early ‐ for any reason ‐ overall acceptability (combined time points) · recent‐onset psychosis (less than three years since the start of psychotic symptoms and either first or second psychotic episode)
Summary of findings table ‐ Cognitive behavioural therapy plus… showed no clear difference in leaving the study early ‐ for any reason ‐ overall acceptability… compared with control (moderate certainty).
1 finding from 1 review
Leaving the study early/ loss to · schizophrenia
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes leaving the study early ‐ for any reason ‐ overall acceptability… compared with CBT plus antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early/ loss to · schizophrenia
Summary of findings table ‐ CBT without antipsychotics showed no clear difference in leaving the study early ‐ for any reason ‐ overall acceptability… compared with no specific treatment (low certainty).
1 finding from 1 review
Leaving the study early/ loss to · schizophrenia
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes leaving the study early ‐ for any reason ‐ overall acceptability… compared with antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early ‐ for any reason ‐ overall acceptability (combined time points) · patients with schizophrenia
Summary of findings table ‐ Continuation may leads to lower leaving the study early due to any reason – overall acceptability… compared with reduction of polypharmacy (low certainty).
1 finding from 1 review
Leaving the study early ‐ for any reason ‐ overall acceptability (combined time points) · patients with schizophrenia
Summary of findings table ‐ Antipsychotic dose reduction probably leads to higher leaving the study early ‐ for any reason ‐ overall acceptability… compared with dose continuation (moderate certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · schizophrenia
Maintenance treatment with antipsychotic drugs leads to lower leaving the study early: due to any reason (acceptability of… compared with placebo/no treatment (high certainty).
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction and acceptability of treatment (medium term) ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether ECT plus standard care changes satisfaction and acceptability of treatment (medium term) ‐ leaving… compared with standard care (very low certainty).
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Acceptability of treatment: Leaving the study early · patients with antipsychotic‐induced TD
It is very uncertain whether the intervention changes acceptability of treatment: Leaving the study early (very low certainty).
1 finding from 1 review
Leaving the study early · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether anticholinergic medication changes acceptability of the treatment: leaving the study early compared with other treatments (very low certainty).
1 finding from 1 review